Академический Документы
Профессиональный Документы
Культура Документы
Supporting
Evidence
Citations
Efficacy 4
VUR 4
VUR - Comparison of Therapies 9
VUR - Complicated Cases 11
VUR - Cost Analysis 13
VUR - Diagnostic 13
VUR - Quality of Life 14
VUR - Technique 15
Safety16
Calcification 16
Malpositioning 16
Migration 16
New Contralateral Versicoureteral Reflux NCVUR 16
Obstruction 16
Tissue Changes 17
Urinary Tract Infection 17
VUR19
Antibiotic Prophylaxis 19
Comparison of Therapies 19
Cost Analysis 19
Diagnostic 20
Management 20
Spontaneous Reflux Resolution 20
Clicking on any citation will show the corresponding abstract. To return to this page click on the Back to Contents Page
link at the bottom of each page.
Abtracts are sourced, where possible, from Pubmed (owned by the National Center for Biotechnology Information (NCBI)).
For full text articles see the publisher of the article for more details. Full text articles are not provided in this document.
Some pages in this dfocument may provide links to external internet sites. Oceana Therapeutics Ltd. is not responsible for
the availability or content of these external sites, nor does Oceana Therapeutics Ltd. endorse, warrant, or guarantee the
products, services, or information described or offered at these other Internet sites.
Abstracts
Efficacy21
VUR 21
VUR - Comparison of Therapies 84
VUR - Complicated Cases 110
VUR - Cost Analysis 139
VUR - Diagnostic 141
VUR - Quality of Life 152
VUR - Technique 153
Safety 163
Calcification 163
Malpositioning 166
Migration 167
New Contralateral Versicoureteral Reflux NCVUR 168
Obstruction 169
Tissue Changes 173
Urinary Tract Infection 177
VUR 183
Antibiotic Prophylaxis 183
Comparison of Therapies 186
Cost Analysis 193
Diagnostic 195
Management 198
Spontaneous Reflux Resolution 202
Efficacy Deflux Supporting Evidence
Citations
Efficacy
VUR
Bioi M, Todori J, Budimir D, Cvitkovi Roi A, Pogoreli Z, Juri I, unjar T. (2012)
Endoscopic treatment of vesicoureteral reflux in children with subureteral dextranomer/hyaluronic
acid injection: a single-centre, 7-year experience. Can J Surg. 2012 Oct;55(5):301-6.
Kaye JD, Srinivasan AK, Delaney C, Cerwinka WH, Elmore JM, Scherz HC, Kirsch AJ. (2012)
Clinical and radiographic results of endoscopic injection for vesicoureteral reflux: defining
measures of success. J Pediatr Urol. 2012 Jun;8(3):297-303
Kalisvaart JF, Scherz HC, Cuda S, Kaye JD, Kirsch AJ. (2011)
Does compliance status predict clinical status in patients undergoing endoscopic management of
vesico-ureteral reflux? J Pediatr Urol. 2011 Dec;7(6):644-9.
Rivilla F. (2011)
Endoscopic treatment of vesicoureteral reflux in a paediatric surgery ambulatory unit. J Minim
Access Surg. 2011 Apr;7(2):132-5.
Tanikaze S, Osa Y, Tada M, Goya N, Asanuma H, Yamazaki Y, Shimada K, Sugita Y, Goto T, Yamaguchi
T. (2010)
Dextranomer beads in stabilized non-animal sodium hyaluronate gel (NASHA/Dx gel) for
vesicoureteral reflux: multi-center study in Japanease patients Nihon Hinyokika Gakkai Zasshi. 2010
Jul;101(5):676-82.
Lckgren G. (2009)
Endoscopic treatment of vesicoureteral reflux: Current status. Indian J Urol. 2009 Jan;25(1):34-9.
Dave S, Lorenzo AJ, Khoury AE, Braga LH, Skeldon SJ, Suoub M, Farhat W, Pippi Salle JL, Bgli DJ.
(2008)
Learning from the learning curve: factors associated with successful endoscopic correction of
vesicoureteral reflux using dextranomer/hyaluronic acid copolymer. J Urol. 2008 Oct;180(4
Suppl):1594-9
Migulez Lago C, Moreno Romn J, Garca Mrida M, Galiano Duro E, Mieles Cerchar M, Ibez
Cerrato F. (2008)
Endoscopic treatment of complicated vesicoureteral reflux grades III-V in infants under the age of
one year Arch Esp Urol. 2008 Mar;61(2):284-90.
Nortes Cano L, Zambudio Carmona G, Guirao Piera MJ, Ruiz Jimnez JI. (2008)
Endoscopic treatment of primary vesicoureteral reflux in childhood. Review of 989 cases in a 9
years period Cir Pediatr. 2008 Jul;21(3):173-80
Escala Aguirre JM, Retamal Pinto G, Cadena Gonzlez Y, Lpez Egaa PJ, Letelier Cancino N, Zubieta
Acua R. (2007)
Endoscopic treatment with Deflux for primary vesicoureteral reflux Actas Urol Esp. 2007
Sep;31(8):880-4
Elder JS, Diaz M, Caldamone AA, Cendron M, Greenfield S, Hurwitz R, Kirsch A, Koyle MA, Pope J,
Shapiro E. (2006)
Endoscopic Therapy for Vesicoureteral Reflux: A Meta-Analysis. I. Reflux Resolution and Urinary
Tract Infection J Urol. 2006 Feb;175(2):716-22.
Kim SO, Shin BS, Hwang IS, Hwang EC, Oh KJ, Jung SI, Kang TW, Kwon D, Park K, Ryu SB. (2011)
Clinical efficacy and safety in children with vesicoureteral reflux of a single injection of two
different bulking agents--polydimethylsiloxane (Macroplastique) or dextranomer/hyaluronic acid
copolymer (Deflux): a short-term prospective comparative study. Urol Int. 2011;87(3):299-303.
Cabezal Barbancho D, Gmez Fraile A, Lpez Vzquez F, Lpez Daz M, Aransay Bramtot A. (2008)
Our experience using various injectable materials for the endoscopic treatment of vesicoureteral
reflux Arch Esp Urol. 2008 Mar;61(2):269-77.
Elmore JM, Kirsch AJ, Heiss EA, Gilchrist A, Scherz HC. (2008)
Incidence of Urinary Tract Infections in Children After Successful Ureteral Reimplantation Versus
Endoscopic Dextranomer/Hyaluronic Acid Implantation J Urol. 2008 Jun;179(6):2364-7
Escala Aguirre JM, Cadena Gonzlez Y, Retamal Pinto G, Lpez Egaa PJ, Letelier Cancino N, Zubieta
Acua R. (2008)
Endoscopic treatment of vesicoureteral reflux (VUR). Comparison of various substances. Long-term
results Arch Esp Urol. 2008 Mar;61(2):297-300.
Terry W. Hensle MD, Grace Hyun, MD, Amy L. Grogg, PharmD, Manan B. Shah, PhD, PharmD (2006)
Assessing the effectiveness of endoscopic injection in treating patients with Vesicoureteral reflux
for the reduction of urinary tract infections
Presented at the 2006 Annual Meeting of the American Academy of Pediatrics, Atlanta, GA. October
7-10,2006
Argelles Salido E, Garca Merino F, Milln Lpez A, Fernndez Hurtado M, Borrero Fernndez J. (2005)
Complex vesicoureteral reflux. Our experience Actas Urol Esp. 2005 Jul-Aug;29(7):685-92
Kraft KH, Molitierno JA Jr, Dewhurst L, Geers C, Gunderson K, Scherz HC, Kirsch AJ. (2011)
Is endoscopic injection therapy a reasonable treatment option for low-grade vesicoureteral reflux
in association with overactive bladder? Urology. 2011 Sep;78(3):675-8
Romero NP, Romo MI, Vegas AG, Izquierdo JB, Varela JC, Arteche AH, Moyano AS. (2010)
Deflux injections for vesicoureteral reflux in transplanted kidneys. Transplant Proc. 2010
Oct;42(8):2892-5.
Vemulakonda VM, Koyle MA, Lendvay TS, Risk MC, Kirsch AJ, Cheng EY, Cisek LJ, Campbell JB. (2010)
Endoscopic treatment of symptomatic refluxing renal transplant ureteroneocystostomies in children
Pediatr Transplant. 2010 Mar;14(2):212-5
Estornell Moragues F, Serrano Durb A, Domnguez Hinarejos C, Ayuso Gonzlez L, Martnez Verduch
M, Garca Ibarra F. (2008)
Endoscopic treatment of vesicoureteral reflux in pediatric patients with the diagnosis of neurogenic
bladder. Results and long-term outcome Arch Esp Urol. 2008 Mar;61(2):278-83.
Fernndez Hurtado MA, Barrero Candau R, Argelles Salido E, Fernndez Pineda I, Garca Merino F.
(2008)
The efficacy of endoscopic treatment for secondary vesicoureteral reflux. Analysis of a series of 142
cases Arch Esp Urol. 2008 Mar;61(2):311-5.
Routh JC, Kramer SA, Inman BA, Ashley RA, Wolpert JJ, Vandersteen DR, Husmann DA, Reinberg Y.
(2008)
Utility of dextranomer/hyaluronic acid injection in setting of bladder and ureteral anomalies.
Urology. 2008 Mar;71(3):435-8.
Jung C, DeMarco RT, Lowrance WT, Pope JC 4th, Adams MC, Dietrich MS, Brock JW 3rd. (2007)
Subureteral injection of dextranomer/hyaluronic acid copolymer for persistent vesicoureteral
reflux following ureteroneocystostomy. J Urol. 2007 Jan;177(1):312-5.
Perez-Brayfield M, Kirsch AJ, Hensle TW, Koyle MA, Furness P, Scherz HC. (2004)
Endoscopic treatment with dextranomer/hyaluronic acid for complex cases of vesicoureteral reflux
J Urol. 2004 Oct;172(4 Pt 2):1614-6.
VUR - Diagnostic
Hidas G, Soltani T, Lusch A, Khoury AE. (2012)
Is the appearance of the Deflux Mound predictive of Reflux Resolution? J Urol. 2012 Nov 27. pii:
S0022-5347(12)05619-4. doi: 10.1016/j.juro.2012.11.110. [Epub ahead of print]
Zamilpa I, Koyle MA, Grady RW, Joyner BD, Shnorhavorian M, Lendvay TS. (2011)
Can we rely on the presence of dextranomer-hyaluronic acid copolymer mounds on ultrasound
to predict vesicoureteral reflux resolution after injection therapy J Urol. 2011 Jun;185(6
Suppl):2536-41.
VUR - Technique
Kajbafzadeh AM, Tourchi A. (2012)
Usefulness of concomitant autologous blood and dextranomer/hyaluronic acid copolymer injection
to correct vesicoureteral reflux. J Urol. 2012 Sep;188(3):948-52
Kalisvaart JF, Scherz HC, Cuda S, Kaye JD, Kirsch AJ. (2012)
Intermediate to long-term follow-up indicates low risk of recurrence after Double HIT endoscopic
treatment for primary vesico-ureteral reflux. J Pediatr Urol. 2012 Aug;8(4):359-65
Bennett SD, Foot LM, Abel EJ, Snow BW, Cartwright PC, Devries CR, Wallis MC. (2010)
Is there a learning curve for subureteric injection of dextranomer/hyaluronic acid in the treatment
of vesicoureteral reflux? J Pediatr Urol. 2010 Apr;6(2):122-4.
Safety
Calcification
Palagiri AV, Dangle PP. (2011)
Distal ureteral calcification secondary to deflux injection: a reality or myth? Urology. 2011
May;77(5):1217-9.
Cerwinka WH, Kaye JD, Scherz HC, Kirsch AJ, Grattan-Smith JD. (2010)
Radiologic features of implants after endoscopic treatment of vesicoureteral reflux in children. AJR
Am J Roentgenol. 2010 Jul;195(1):234-40.
Cerwinka WH, Qian J, Easley KA, Scherz HC, Kirsch AJ. (2009)
Appearance of dextranomer/hyaluronic Acid copolymer implants on computerized tomography after
endoscopic treatment of vesicoureteral reflux in children. J Urol. 2009 Mar;181(3):1324-8;
Malpositioning
Ben-Meir D, Morgenstern S, Sivan B, Efrat R, Livne PM. (2012)
Histology proved malpositioning of dextranomer/hyaluronic acid in submucosal ureter in patients
after failed endoscopic treatment of vesicoureteral reflux. J Urol. 2012 Jul;188(1):258-61
Migration
Stenberg AM, Sundin A, Larsson BS, Lackgren G and Stenberg A. (1997)
Lack of distant migration after injection of a 125iodine labeled dextranomer based implant into
the rabbit bladder. J Urol. 1997 Nov;158(5):1937-41.
Obstruction
Garca Mrida M, Moreno Romn J, Migulez Lago C, Rius Daz F, Mieles Cerchar M, Galiano Duro E.
(2008)
Postoperative ureteral obstruction after endoscopic antireflux therapy Arch Esp Urol. 2008
Mar;61(2):328-34.
Vandersteen DR, Routh JC, Kirsch AJ, Scherz HC, Ritchey ML, Shapiro E, Wolpert JJ, Pfefferle H,
Reinberg Y. (2006)
Postoperative ureteral obstruction after subureteral injection of dextranomer/hyaluronic acid
copolymer. J Urol. 2006 Oct;176(4 Pt 1):1593-5.
Tissue Changes
Lpez Daz M, Lpez Vzquez F, Gmez Fraile A, Aransay Bramtot A, Cabezal Barbancho D, Tejedor
Snchez R. (2008)
Endoscopic treatment of vesicoureteral reflux: histologic findings Arch Esp Urol. 2008
Mar;61(2):112-6
Routh JC, Ashley RA, Sebo TJ, Vandersteen DR, Slezak J, Reinberg Y. (2007)
Histopathological changes associated with dextranomer/hyaluronic acid injection for pediatric
vesicoureteral reflux. J Urol. 2007 Oct;178(4 Pt 2):1707-10
Diagnostic
Management
Kenneth B. Roberts, MD, Chairperson
Stephen M. Downs, MD, MS
Stanley Hellerstein, MD
Michael J. Holmes, MD, PhD
Robert L. Lebowitz, MD
Jacob A. Lohr, MD
Linda D. Shortliffe, MD
Russell W. Steele, MD (1999)
Committee on Quality Improvement, Subcommittee on Urinary Tract Infection - Practice Parameter:
The Diagnosis, Treatment, and Evaluation of the Initial Urinary Tract Infection in Febrile Infants
and Young Children Pediatrics 1999;103;843
VUR
Antibiotic Prophylaxis
Copp HL, Nelson CP, Shortliffe LD, Lai J, Saigal CS, Kennedy WA and the Urological Diseases in America
Project (2010)
Compliance With Antibiotic Prophylaxis in Children With Vesicoureteral Reflux: Results From a
National Pharmacy Claims Database J Urol. 2010 May;183(5):1994-9
Comparison of Therapies
Nagler EVT, Williams G, Hodson EM, Craig JC. (2011)
Interventions for primary vesicoureteric reflux (Review) Cochrane Database Syst Rev. 2011 Jun
15;(6):CD001532
Elder JS (2008)
Therapy for Vesicoureteral Reflux: Antibiotic Prophylaxis, Urotherapy, Open Surgery, Endoscopic
Injection, or Observation? Curr Urol Rep. 2008 Mar;9(2):143-50.
Hodson EM, Wheeler DM, Vimalchandra D, Smith GH, Craig JC. (2007)
Interventions for primary vesicoureteric reflux Cochrane Database Syst Rev. 2007 Jul
18;(3):CD001532.
Cost Analysis
Benoit RM, Peele PB, Docimo SG. (2006)
The cost-effectiveness of dextranomer/hyaluronic acid copolymer for the management of
vesicoureteral reflux. 1: substitution for surgical management. Urol 2006; 176: 158892
Diagnostic
Shiraishi K, Yoshino K, Watanabe M, Matsuyama H, Tanikaze S. (2010)
Risk Factors for Breakthrough Infection in Children With Primary Vesicoureteral Reflux J Urol. 2010
Oct;184(4):1574-5;
Management
Nelson CP, Copp HL, Lai J, Saigal CS; Urologic Diseases in America Project. (2009)
Is availability of endoscopy changing initial management of vesicoureteral reflux? J Urol. 2009
Sep;182(3):1152-7
Lendvay TS, Sorensen M, Cowan CA, Joyner BD, Mitchell MM, Grady RW (2006)
The evolution of vesicoureteral reflux management in the era of dextranomer/hyaluronic acid
copolymer: a pediatric health information system database study. J Urol. 2006 Oct;176(4 Pt
2):1864-7.
Schwab CW Jr, Wu HY, Selman H, Smith GH, Snyder HM 3rd, Canning DA. (2002)
Spontaneous resolution of vesicoureteral reflux: a 15-year perspective. J Urol. 2002
Dec;168(6):2594-9.
Abstracts
Efficacy
VUR
Are there predictive factors for the outcome of endoscopic treatment of grade
III-V vesicoureteral reflux with dextranomer/hyaluronic acid in children?
Altug U, Cakan M, Yilmaz S, Yalinkaya F.
Pediatr Surg Int. 2007 Jun;23(6):585-9.
Dextranomer/hyaluronic acid (Dx/HA) copolymer has been used widely for the treatment
of vesicoureteral reflux (VUR) in children since 2001. However, the factors that influence
the outcome of injection therapy with Dx/HA have remained unclear. In this study, we
retrospectively evaluated the outcomes in 101 consecutive children to determine the cure
and to identify the factors that can impact treatment outcomes of Dx/HA injection.
Endoscopic treatment with Dx/HA was performed in 133 ureters, in 101 patients with grade
III-V VUR. Of the patients, 68 (67.3%) were girls and the mean age was 6.5 years. Before
and after the treatment, the presence and grades of VUR were determined by voiding
cystourethrograms. The patients age, gender, laterality, preoperative reflux grade, ureteral
duplication, morphology of ureteral orifice, renal hypoplasia and experience with surgery
were assessed as predictive factors related to the success rates of Dx/HA injection therapy.
The cure rates were 54.8% after the first injection, 66.9% after the second and 73.6% after the
third injection. Patients with a high grade (grade IV or V), duplicated system, golf hole-shaped
orifice and renal hypoplasia had significantly lower cure rates (P<0.05). Experience with the
technique also correlated with the positive outcome of the procedure. New contralateral
vesicoureteral reflux developed in five (7.2%) patients with unilateral VUR, and all of them
resolved spontaneously during the first year of followup. No treatment-related significant
complication was encountered.
Although, endoscopic treatment of VUR with Dx/HA provides a high rate of success in children
with medium or high grade VUR, treatment failure may be seen in some patients. However, we
showed that endoscopic treatment with Dx/HA was effective in selected patients with grade
V VUR, and we emphasize the need for further large-scale studies to confirm our findings.
http://www.ncbi.nlm.nih.gov/pubmed/17356857
The Swedish Reflux Trial in Children: III. Urinary Tract Infection Pattern
Brandstrm P, Esbjrner E, Herthelius M, Swerkersson S, Jodal U, Hansson S.
J Urol. 2010 Jul;184(1):286-91
Purpose: We evaluated the difference in the febrile urinary tract infection rate in small
children with dilating vesicoureteral reflux randomly allocated to 3 management alternatives,
including antibiotic prophylaxis, endoscopic treatment or surveillance only as the control.
Materials and Methods: At 23 centers a total of 203 children were included in the study,
including 128 girls and 75 boys 1 to younger than 2 years. Vesicoureteral reflux grade III in
126 cases and IV in 77 was detected after a febrile urinary tract infection (194) after prenatal
screening (9). Voiding cystourethrography and dimercapto-succinic acid scintigraphy were
done before randomization and after 2 years. The febrile urinary tract infection rate was
analyzed by the intent to treat principle.
Results: We noted a total of 67 febrile recurrences in 42 girls and a total of 8 in 7 boys (p
0.0001). There was a difference in the recurrence rate among treatment groups in girls with
febrile infection in 8 of 43 (19%) on prophylaxis, 10 of 43 (23%) with endoscopic therapy and
24 of 42 (57%) on surveillance (p 0.0002). In girls the recurrence rate was associated with
persistent reflux after 2 years (p 0.0095). However, reflux severity (grade III or IV) at study
entry did not predict recurrence.
Conclusions: In this randomized, controlled trial there was a high rate of recurrent febrile
urinary tract infection in girls older than 1 year with dilating vesicoureteral reflux at study
entry but not in boys. Antibiotic prophylaxis and endoscopic treatment decreased the infection
rate.
http://www.ncbi.nlm.nih.gov/pubmed/20488494
VUR - Diagnostic
VUR - Technique
Safety
Calcification
Malpositioning
Migration
Obstruction
Tissue Changes
Diagnostic
Management
VUR
Antibiotic Prophylaxis
Comparison of Therapies
developing kidney damage over the course of two to three years.The added benefit of surgical
or endoscopic correction of VUR over antibiotic treatment alone remains unclear. Eight
children would require combined surgical and antibiotic treatment to prevent one additional
child developing febrile UTI by five years, but it would not cause fewer children developing
renal damage.
http://www.ncbi.nlm.nih.gov/pubmed/17931481
Cost Analysis
Diagnostic
Management